celecoxib and Allodynia studies

celecoxib and Allodynia

celecoxib has been researched along with Allodynia in 51 studies

Research Excerpts

Excerpt	Relevance	Reference
"To evaluate and compare the effects of salmon calcitonin (sCT) and celecoxib (CLX) on cartilage, subchondral bone and tactile allodynia in a rat model of lumbar facet joint (FJ) osteoarthritis (OA)."	7.91	Salmon calcitonin exerts better preventive effects than celecoxib on lumbar facet joint degeneration and long-term tactile allodynia in rats. ( Chen, T; Dai, M; Gou, Y; Kong, Q; Li, H; Lv, Q; Shao, L; Song, H; Tian, F; Zhang, L; Zhang, Y, 2019)
"The non-steroidal anti-inflammatory drug celecoxib has long been used for reducing pain, in spite of moderate gastrointestinal side effects."	7.85	The Analgesic Effects of Celecoxib on the Formalin-induced Short- and Long-term Inflammatory Pain. ( Guo, XJ; Liang, JC; Sun, Y; Tang, K; Wang, HY; Wang, Y; Wang, YT; Yin, JB; Zhao, YQ, 2017)
"Lornoxicam exhibits strong analgesic but weak antipyretic effects in rats with paw inflammation."	7.75	The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. ( Arai, I; Futaki, N; Harada, M; Hashimoto, Y; Honma, Y; Hoshi, K; Nakaike, S; Sugimoto, M, 2009)
"The purpose of this study is to clarify involvement ratios between central and peripheral cyclooxygenase (COX)-2 in rat inflammatory pain models, by evaluating celecoxib and [6-chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]acetic acid (CIAA) on carrageenan-induced mechanical and thermal hyperalgesia."	7.74	Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA. ( Kita, Y; Murata, Y; Okumura, T; Sakakibara, A, 2008)
"Formalin (0."	5.42	Celecoxib reduces hyperalgesia and tactile allodynia in diabetic rats. ( Bermúdez-Ocaña, DY; Ble-Castillo, JL; Díaz-Zagoya, JC; Granados-Soto, V; Juárez-Rojop, IE; Morales-Hernández, PE; Torres-Lopez, JE; Tovilla-Zárate, CA, 2015)
"The non-steroidal anti-inflammatory drug celecoxib has long been used for reducing pain, in spite of moderate gastrointestinal side effects."	3.85	The Analgesic Effects of Celecoxib on the Formalin-induced Short- and Long-term Inflammatory Pain. ( Guo, XJ; Liang, JC; Sun, Y; Tang, K; Wang, HY; Wang, Y; Wang, YT; Yin, JB; Zhao, YQ, 2017)
" The compounds 3a, 3b, 3c, 3e, and 3f presented anti-hyperalgesic action, while the compounds 3a, 3c, 3d, 3f, and 3g exhibited anti-edematogenic effects, without causing locomotive disorders in animals, thus making them comparable to Celecoxib in an arthritic pain model."	3.81	Regioselectively controlled synthesis of 3(5)-(trifluoromethyl)pyrazolylbenzenesulfonamides and their effects on a pathological pain model in mice. ( Bonacorso, HG; Brusco, I; Canova, B; da Silva, TV; de Souza, ON; Dos Santos, JM; Lobo, MM; Machado, P; Martins, MA; Oliveira, SM; Timmers, LF; Zanatta, N, 2015)
" These results suggest that ceftriaxone, particularly in combinations with ibuprofen, celecoxib, paracetamol, or levetiracetam, may provide useful approach to the clinical treatment of inflammation-related pain."	3.80	Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents. ( Boškovic, BD; Kovacevic, JM; Micov, AM; Stepanovic-Petrovic, RM; Tomic, MA, 2014)
" In particular, the glycine derivative proved to be extremely active in suppressing hyperalgesia and edema."	3.80	Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors. ( Alfonso, S; Anzini, M; Battilocchio, C; Biava, M; Calderone, V; Colovic, M; Consalvi, S; Di Capua, A; Di Cesare Mannelli, L; Dovizio, M; Ghelardini, C; Giordani, A; Martelli, A; Patrignani, P; Persiani, S; Poce, G; Rossi, A; Sautebin, L; Testai, L, 2014)
" This study characterized the manner in which levetiracetam interacts with analgesics (ibuprofen, celecoxib, and paracetamol) and caffeine to suppress hyperalgesia in a model of localized inflammation."	3.79	Levetiracetam interacts synergistically with nonsteroidal analgesics and caffeine to produce antihyperalgesia in rats. ( Micov, AM; Stepanović-Petrović, RM; Tomić, MA, 2013)
" Additionally, LASSBio-1135 (3a) presented activity similar to celecoxib (1) regarding the reduction of the carrageenan-induced rat paw edema (33% of inhibition at 100 micromol/kg, po)."	3.75	Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. ( Barreiro, EJ; da Silva, LL; de Lima, CK; Fraga, CA; Lacerda, RB; Miranda, AL; Romeiro, NC, 2009)
"Lornoxicam exhibits strong analgesic but weak antipyretic effects in rats with paw inflammation."	3.75	The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. ( Arai, I; Futaki, N; Harada, M; Hashimoto, Y; Honma, Y; Hoshi, K; Nakaike, S; Sugimoto, M, 2009)
"The purpose of this study is to clarify involvement ratios between central and peripheral cyclooxygenase (COX)-2 in rat inflammatory pain models, by evaluating celecoxib and [6-chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]acetic acid (CIAA) on carrageenan-induced mechanical and thermal hyperalgesia."	3.74	Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA. ( Kita, Y; Murata, Y; Okumura, T; Sakakibara, A, 2008)
" This work led to the identification of 1i (4-[5-(4-methylphenyl)-3-(trifluoromethyl)- H-pyrazol-1-yl]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis."	3.69	Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). ( Bertenshaw, SR; Burton, EG; Carter, JS; Cogburn, JN; Collins, PW; Docter, S; Graneto, MJ; Gregory, SA; Isakson, PC; Koboldt, CM; Lee, LF; Malecha, JW; Miyashiro, JM; Penning, TD; Perkins, WE; Rogers, RS; Rogier, DJ; Seibert, K; Talley, JJ; Veenhuizen, AW; Yu, SS; Zhang, YY, 1997)
"To assess hyperalgesia in persistent pain patients we performed an additional analysis on patients reporting VAS>30 at 12 months."	2.82	Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition. ( Filippini-de Moor, GP; Steegers, MA; van Helmond, N; Vissers, KC; Wilder-Smith, OH, 2016)
"Mechanical hyperalgesia, joint edema, leukocyte recruitment to the joint and damage to cartilage in experimental arthritis and cytotoxicity, spread of disease, phagocytic activity and nitric oxide (NO) and hydrogen peroxide production by macrophages were evaluated."	1.91	1,4-Diaryl-1,2,3-triazole neolignan-celecoxib hybrids inhibit experimental arthritis induced by zymosan. ( B Carvalho, D; Baroni, ACM; Bonfá, IS; Candeloro, L; das Neves, AR; Felipe, JL; Ferreira, GIS; Lencina, JS; Lossavaro, PKMB; Silva-Filho, SE; Souza, MIL; Toffoli-Kadri, MC, 2023)
"Mechanical allodynia, heat hyperalgesia, biased weight-bearing, and hindpaw thickness were assessed 0."	1.62	Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats. ( Britch, SC; Craft, RM; Hewitt, KA, 2021)
"Pain is a prevalent PD's non-motor symptom with a higher prevalence of analgesic drugs prescription for patients."	1.56	Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. ( Bortolanza, M; Crivelaro do Nascimento, G; Del Bel, EA; Ferrari, DP; Ferreira-Junior, NC; Guimaraes, FS, 2020)
"Celecoxib had no effect on muscular mechanical hyperalgesia, when orally administered 24 h after lengthening contractions."	1.51	Nonsteroidal anti-inflammatory drugs and acetaminophen ameliorate muscular mechanical hyperalgesia developed after lengthening contractions via cyclooxygenase-2 independent mechanisms in rats. ( Mikoshiba, S; Shimodaira, T; Taguchi, T, 2019)
"The prevention of this hyperalgesia by diclofenac (1-10μg), the inhibitors of COX-1 SC-560 (0."	1.46	Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice. ( Álvarez, MG; Baamonde, A; Cernuda-Cernuda, R; Fernández-García, MT; Folgueras, AR; García-Domínguez, M; González-Rodríguez, S; Hidalgo, A; Lastra, A; Menéndez, L, 2017)
"We tested whether this parameter and tactile allodynia, the standard pain measure in preclinical studies, show parallels in their response to analgesics and basic mechanisms."	1.46	Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia. ( Cañizares, FJ; Cobos, EJ; Entrena, JM; Fernández-Segura, E; Montilla-García, Á; Perazzoli, G; Portillo-Salido, E; Tejada, MÁ, 2017)
"Formalin (0."	1.42	Celecoxib reduces hyperalgesia and tactile allodynia in diabetic rats. ( Bermúdez-Ocaña, DY; Ble-Castillo, JL; Díaz-Zagoya, JC; Granados-Soto, V; Juárez-Rojop, IE; Morales-Hernández, PE; Torres-Lopez, JE; Tovilla-Zárate, CA, 2015)
"In a diabetic neuropathic pain model, pretreatment with celecoxib, L-NIL and 7-Ni, significantly increased the antihyperalgesic activity of both Met-F-AEA and AM 1241."	1.42	Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy. ( Bujalska-Zadrożny, M; de Cordé, A; Pawlik, K, 2015)
"Mechanical allodynia and thermal hyperalgesia induced by CCI were markedly attenuated by celecoxib from 5 to 14 days after surgery, and relieved by ibuprofen treatment from 7 to 10 days after surgery."	1.36	Cyclooxygenase inhibitors suppress the expression of P2X(3) receptors in the DRG and attenuate hyperalgesia following chronic constriction injury in rats. ( Guo, QL; Huang, CS; Wang, Y; Yan, JQ; Zhang, X; Zou, WY, 2010)
"Indomethacin (sc) reversed CG-induced hyperalgesia only to basal levels (an anti-hyperalgesic effect)."	1.36	Peripheral mu-, kappa- and delta-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia. ( Bakhle, YS; Correa, JD; Dos Reis, WG; Ferreira-Alves, DL; Francischi, JN; Paiva-Lima, P; Rezende, RM, 2010)
"However, lumiracoxib only produced anti-hyperalgesia."	1.36	Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity? ( Bakhle, YS; de Francischi, JN; dos Reis, WG; Ferreira-Alves, DL; Gassani, BC; Paiva-Lima, P; Rezende, RM, 2010)
"Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2)."	1.36	Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats. ( Bakhle, YS; Camêlo, VM; de Francischi, JN; Dos Reis, WG; Paiva-Lima, P; Rezende, RM, 2010)
"Swelling and mechanical and thermal hyperalgesia were assessed before and for 28 days after the onset of arthritis."	1.34	Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. ( Anand, P; Essex, D; Feldmann, M; Inglis, JJ; Notley, CA; Williams, R; Wilson, AW, 2007)
"Celecoxib abrogated carrageenan-induced hyperalgesia in the hind paw accompanied by a decrease in PGE2 content in paw exudates and cerebrospinal fluid in a dose-related manner, with an ED30 = 0."	1.33	Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor. ( Fukunaga, M; Hayashi, A; Kimoto, A; Kobayashi, S; Miyata, K; Noguchi, M; Sasamata, M; Yoshino, T, 2005)
"CION caused ipsilateral cold hyperalgesia between Days 2 and 12, which peaked on Days 4 (sham 15."	1.33	Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs. ( Chichorro, JG; Rae, GA; Souza, GE; Zampronio, AR, 2006)
"Paw edema and hyperalgesia were monitored from day zero to day 21 after induction as signs of arthritis development."	1.32	Role of endogenous glucocorticoids in hyperalgesia and edema in old arthritic rats. ( Alves, DL; Francischi, JN; Pereira, LS; Tatsuo, MA; Yokoro, CM, 2003)
"3."	1.32	Pharmacological characterisation of a rat model of incisional pain. ( Boulet, J; Gottshall, S; Harrison, J; Mark, L; Pearson, M; Walker, K; Whiteside, GT, 2004)
"Ibuprofen treatment reversed PGE2 levels in injured nerves and DRG, whereas celecoxib blocked increased PGE2 levels only in nerves."	1.32	Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. ( Marziniak, M; Schäfers, M; Sommer, C; Sorkin, LS; Yaksh, TL, 2004)
"In addition, formalin-induced secondary hyperalgesia was locally prevented by pre-but not post-celecoxib treatment."	1.32	Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. ( Avila, MN; da Motta, PG; Duarte, ID; Francischi, JN; Tatsuo, MA; Veiga, AP, 2004)
"2."	1.31	Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. ( Bakhle, YS; Chaves, CT; Ferreira-Alves, DL; Francischi, JN; Lima, AS; Moura, AC; Rocha, OA, 2002)
" Both exhibit good oral bioavailability and are potent in standard models of pain, fever, and inflammation yet have a much reduced effect on the GI integrity of rats compared to standard nonsteroidal antiflammatory drugs."	1.30	2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. ( Black, WC; Brideau, C; Chan, CC; Charleson, S; Chauret, N; Claveau, D; Ethier, D; Gordon, R; Greig, G; Guay, J; Hughes, G; Jolicoeur, P; Leblanc, Y; Nicoll-Griffith, D; Ouimet, N; Prasit, P; Riendeau, D; Visco, D; Wang, Z; Xu, L, 1999)

Research

Studies (51)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (5.88)	18.2507
2000's	19 (37.25)	29.6817
2010's	25 (49.02)	24.3611
2020's	4 (7.84)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

3 (5.88)

18.2507

2000's

19 (37.25)

29.6817

2010's

25 (49.02)

24.3611

2020's

4 (7.84)

2.80

Authors

Authors	Studies
Penning, TD	1
Talley, JJ	2
Bertenshaw, SR	1
Carter, JS	1
Collins, PW	1
Docter, S	1
Graneto, MJ	1
Lee, LF	1
Malecha, JW	1
Miyashiro, JM	1
Rogers, RS	1
Rogier, DJ	1
Yu, SS	1
Burton, EG	1
Cogburn, JN	1
Gregory, SA	1
Koboldt, CM	2
Perkins, WE	1
Seibert, K	2
Veenhuizen, AW	1
Zhang, YY	1
Isakson, PC	2
Black, WC	1
Brideau, C	1
Chan, CC	1
Charleson, S	1
Chauret, N	1
Claveau, D	1
Ethier, D	1
Gordon, R	1
Greig, G	1
Guay, J	1
Hughes, G	1
Jolicoeur, P	1
Leblanc, Y	1
Nicoll-Griffith, D	1
Ouimet, N	1
Riendeau, D	1
Visco, D	1
Wang, Z	1
Xu, L	1
Prasit, P	1
Szabó, G	1
Fischer, J	1
Kis-Varga, A	1
Gyires, K	1
Lacerda, RB	1
de Lima, CK	1
da Silva, LL	1
Romeiro, NC	1
Miranda, AL	1
Barreiro, EJ	1
Fraga, CA	1
Biava, M	2
Porretta, GC	1
Poce, G	2
Battilocchio, C	2
Alfonso, S	2
Rovini, M	1
Valenti, S	1
Giorgi, G	1
Calderone, V	2
Martelli, A	2
Testai, L	2
Sautebin, L	2
Rossi, A	2
Papa, G	1
Ghelardini, C	2
Di Cesare Mannelli, L	2
Giordani, A	2
Anzellotti, P	1
Bruno, A	1
Patrignani, P	2
Anzini, M	2
Consalvi, S	1
Di Capua, A	1
Persiani, S	1
Colovic, M	1
Dovizio, M	1
Parsons, WH	1
Calvo, RR	1
Cheung, W	1
Lee, YK	1
Patel, S	1
Liu, J	1
Youngman, MA	1
Dax, SL	1
Stone, D	1
Qin, N	1
Hutchinson, T	1
Lubin, ML	1
Zhang, SP	1
Finley, M	1
Liu, Y	1
Brandt, MR	1
Flores, CM	1
Player, MR	1
Singh, P	3
Prasher, P	1
Dhillon, P	1
Bhatti, R	3
Lobo, MM	1
Oliveira, SM	1
Brusco, I	1
Machado, P	1
Timmers, LF	1
de Souza, ON	1
Martins, MA	1
Bonacorso, HG	1
Dos Santos, JM	1
Canova, B	1
da Silva, TV	1
Zanatta, N	1
Kaur, S	2
Kumari, P	2
Kaur, B	1
Kaur, M	1
Singh, G	1
Bhatti, M	1
Kaur, J	1
Felipe, JL	1
Bonfá, IS	1
Lossavaro, PKMB	1
Lencina, JS	1
B Carvalho, D	1
Candeloro, L	1
Ferreira, GIS	1
das Neves, AR	1
Souza, MIL	1
Silva-Filho, SE	1
Baroni, ACM	1
Toffoli-Kadri, MC	1
Shimodaira, T	1
Mikoshiba, S	1
Taguchi, T	1
Crivelaro do Nascimento, G	1
Ferrari, DP	1
Guimaraes, FS	1
Del Bel, EA	1
Bortolanza, M	1
Ferreira-Junior, NC	1
Craft, RM	1
Hewitt, KA	1
Britch, SC	1
Zhao, YQ	1
Wang, HY	1
Yin, JB	1
Sun, Y	1
Wang, Y	2
Liang, JC	1
Guo, XJ	1
Tang, K	1
Wang, YT	1
Montilla-García, Á	1
Tejada, MÁ	1
Perazzoli, G	1
Entrena, JM	1
Portillo-Salido, E	1
Fernández-Segura, E	1
Cañizares, FJ	1
Cobos, EJ	1
Gou, Y	1
Tian, F	1
Dai, M	1
Li, H	1
Lv, Q	1
Kong, Q	1
Chen, T	1
Shao, L	1
Song, H	1
Zhang, Y	2
Zhang, L	1
Lee, JY	2
Choi, HY	1
Park, CS	1
Jang, C	1
Lee, KT	1
Youn, I	1
Yune, TY	1
Tomić, MA	2
Micov, AM	2
Stepanović-Petrović, RM	2
Kovacevic, JM	1
Boškovic, BD	1
Bujalska-Zadrożny, M	1
de Cordé, A	1
Pawlik, K	1
Juárez-Rojop, IE	1
Morales-Hernández, PE	1
Tovilla-Zárate, CA	1
Bermúdez-Ocaña, DY	1
Torres-Lopez, JE	1
Ble-Castillo, JL	1
Díaz-Zagoya, JC	1
Granados-Soto, V	1
Qureshi, RA	1
Tian, Y	1
McDonald, MK	1
Capasso, KE	1
Douglas, SR	1
Gao, R	1
Orlova, IA	1
Barrett, JE	1
Ajit, SK	1
Sacan, A	1
van Helmond, N	1
Steegers, MA	1
Filippini-de Moor, GP	1
Vissers, KC	1
Wilder-Smith, OH	1
González-Rodríguez, S	1
Álvarez, MG	1
García-Domínguez, M	1
Lastra, A	1
Cernuda-Cernuda, R	1
Folgueras, AR	1
Fernández-García, MT	1
Hidalgo, A	1
Baamonde, A	1
Menéndez, L	1
Mi, WL	1
Mao-Ying, QL	1
Liu, Q	1
Wang, XW	1
Wang, YQ	1
Wu, GC	1
Futaki, N	1
Harada, M	1
Sugimoto, M	1
Hashimoto, Y	1
Honma, Y	1
Arai, I	1
Nakaike, S	1
Hoshi, K	1
Zhang, X	1
Guo, QL	1
Zou, WY	1
Huang, CS	1
Yan, JQ	1
Correa, JD	1
Paiva-Lima, P	3
Rezende, RM	3
Dos Reis, WG	3
Ferreira-Alves, DL	3
Bakhle, YS	4
Francischi, JN	4
Gassani, BC	1
de Francischi, JN	2
Camêlo, VM	1
Mohy El-Din, MM	1
Senbel, AM	1
Bistawroos, AA	1
El-Mallah, A	1
Nour El-Din, NA	1
Bekhit, AA	1
Abd El Razik, HA	1
Robinson, I	1
Sargent, B	1
Hatcher, JP	1
Mills, CD	1
Nguyen, T	1
Tanga, FY	1
Zhong, C	1
Gauvin, DM	1
Mikusa, J	1
Gomez, EJ	1
Salyers, AK	1
Bannon, AW	1
Bianchi, M	1
Broggini, M	1
Chaves, CT	1
Moura, AC	1
Lima, AS	1
Rocha, OA	1
Yokoro, CM	1
Tatsuo, MA	2
Pereira, LS	1
Alves, DL	1
Chacur, M	1
Longo, I	2
Picolo, G	1
Gutiérrez, JM	1
Lomonte, B	1
Guerra, JL	1
Teixeira, CF	1
Cury, Y	2
Whiteside, GT	1
Harrison, J	1
Boulet, J	1
Mark, L	1
Pearson, M	1
Gottshall, S	1
Walker, K	1
Schäfers, M	1
Marziniak, M	1
Sorkin, LS	1
Yaksh, TL	1
Sommer, C	1
Hsueh, SF	1
Lu, CY	1
Chao, CS	1
Tan, PH	1
Huang, YW	1
Hsieh, SW	1
Hsiao, HT	1
Chung, NC	1
Lin, SH	1
Huang, PL	1
Lyu, PC	1
Yang, LC	1
Zanchet, EM	1
Veiga, AP	1
Duarte, ID	1
Avila, MN	1
da Motta, PG	1
Yoshino, T	1
Kimoto, A	1
Kobayashi, S	1
Noguchi, M	1
Fukunaga, M	1
Hayashi, A	1
Miyata, K	1
Sasamata, M	1
Chichorro, JG	1
Zampronio, AR	1
Souza, GE	1
Rae, GA	1
Okumura, T	1
Sakakibara, A	1
Murata, Y	1
Kita, Y	1
Inglis, JJ	1
Notley, CA	1
Essex, D	1
Wilson, AW	1
Feldmann, M	1
Anand, P	1
Williams, R	1
Lee, IO	1
Seo, Y	1
Smith, CJ	1
Muhammad, J	1
Zweifel, BS	1
Shaffer, A	1
Masferrer, JL	1
Mazario, J	1
Gaitan, G	1
Herrero, JF	1

Studies

Penning, TD

Talley, JJ

Bertenshaw, SR

Carter, JS

Collins, PW

Docter, S

Graneto, MJ

Lee, LF

Malecha, JW

Miyashiro, JM

Rogers, RS

Rogier, DJ

Yu, SS

Burton, EG

Cogburn, JN

Gregory, SA

Koboldt, CM

Perkins, WE

Seibert, K

Veenhuizen, AW

Zhang, YY

Isakson, PC

Black, WC

Brideau, C

Chan, CC

Charleson, S

Chauret, N

Claveau, D

Ethier, D

Gordon, R

Greig, G

Guay, J

Hughes, G

Jolicoeur, P

Leblanc, Y

Nicoll-Griffith, D

Ouimet, N

Riendeau, D

Visco, D

Wang, Z

Xu, L

Prasit, P

Szabó, G

Fischer, J

Kis-Varga, A

Gyires, K

Lacerda, RB

de Lima, CK

da Silva, LL

Romeiro, NC

Miranda, AL

Barreiro, EJ

Fraga, CA

Biava, M

Porretta, GC

Poce, G

Battilocchio, C

Alfonso, S

Rovini, M

Valenti, S

Giorgi, G

Calderone, V

Martelli, A

Testai, L

Sautebin, L

Rossi, A

Papa, G

Ghelardini, C

Di Cesare Mannelli, L

Giordani, A

Anzellotti, P

Bruno, A

Patrignani, P

Anzini, M

Consalvi, S

Di Capua, A

Persiani, S

Colovic, M

Dovizio, M

Parsons, WH

Calvo, RR

Cheung, W

Lee, YK

Patel, S

Liu, J

Youngman, MA

Dax, SL

Stone, D

Qin, N

Hutchinson, T

Lubin, ML

Zhang, SP

Finley, M

Liu, Y

Brandt, MR

Flores, CM

Player, MR

Singh, P

Prasher, P

Dhillon, P

Bhatti, R

Lobo, MM

Oliveira, SM

Brusco, I

Machado, P

Timmers, LF

de Souza, ON

Martins, MA

Bonacorso, HG

Dos Santos, JM

Canova, B

da Silva, TV

Zanatta, N

Kaur, S

Kumari, P

Kaur, B

Kaur, M

Singh, G

Bhatti, M

Kaur, J

Felipe, JL

Bonfá, IS

Lossavaro, PKMB

Lencina, JS

B Carvalho, D

Candeloro, L

Ferreira, GIS

das Neves, AR

Souza, MIL

Silva-Filho, SE

Baroni, ACM

Toffoli-Kadri, MC

Shimodaira, T

Mikoshiba, S

Taguchi, T

Crivelaro do Nascimento, G

Ferrari, DP

Guimaraes, FS

Del Bel, EA

Bortolanza, M

Ferreira-Junior, NC

Craft, RM

Hewitt, KA

Britch, SC

Zhao, YQ

Wang, HY

Yin, JB

Sun, Y

Wang, Y

Liang, JC

Guo, XJ

Tang, K

Wang, YT

Montilla-García, Á

Tejada, MÁ

Perazzoli, G

Entrena, JM

Portillo-Salido, E

Fernández-Segura, E

Cañizares, FJ

Cobos, EJ

Gou, Y

Tian, F

Dai, M

Li, H

Lv, Q

Kong, Q

Chen, T

Shao, L

Song, H

Zhang, Y

Zhang, L

Lee, JY

Choi, HY

Park, CS

Jang, C

Lee, KT

Youn, I

Yune, TY

Tomić, MA

Micov, AM

Stepanović-Petrović, RM

Kovacevic, JM

Boškovic, BD

Bujalska-Zadrożny, M

de Cordé, A

Pawlik, K

Juárez-Rojop, IE

Morales-Hernández, PE

Tovilla-Zárate, CA

Bermúdez-Ocaña, DY

Torres-Lopez, JE

Ble-Castillo, JL

Díaz-Zagoya, JC

Granados-Soto, V

Qureshi, RA

Tian, Y

McDonald, MK

Capasso, KE

Douglas, SR

Gao, R

Orlova, IA

Barrett, JE

Ajit, SK

Sacan, A

van Helmond, N

Steegers, MA

Filippini-de Moor, GP

Vissers, KC

Wilder-Smith, OH

González-Rodríguez, S

Álvarez, MG

García-Domínguez, M

Lastra, A

Cernuda-Cernuda, R

Folgueras, AR

Fernández-García, MT

Hidalgo, A

Baamonde, A

Menéndez, L

Mi, WL

Mao-Ying, QL

Liu, Q

Wang, XW

Wang, YQ

Wu, GC

Futaki, N

Harada, M

Sugimoto, M

Hashimoto, Y

Honma, Y

Arai, I

Nakaike, S

Hoshi, K

Zhang, X

Guo, QL

Zou, WY

Huang, CS

Yan, JQ

Correa, JD

Paiva-Lima, P

Rezende, RM

Dos Reis, WG

Ferreira-Alves, DL

Bakhle, YS

Francischi, JN

Gassani, BC

de Francischi, JN

Camêlo, VM

Mohy El-Din, MM

Senbel, AM

Bistawroos, AA

El-Mallah, A

Nour El-Din, NA

Bekhit, AA

Abd El Razik, HA

Robinson, I

Sargent, B

Hatcher, JP

Mills, CD

Nguyen, T

Tanga, FY

Zhong, C

Gauvin, DM

Mikusa, J

Gomez, EJ

Salyers, AK

Bannon, AW

Bianchi, M

Broggini, M

Chaves, CT

Moura, AC

Lima, AS

Rocha, OA

Yokoro, CM

Tatsuo, MA

Pereira, LS

Alves, DL

Chacur, M

Longo, I

Picolo, G

Gutiérrez, JM

Lomonte, B

Guerra, JL

Teixeira, CF

Cury, Y

Whiteside, GT

Harrison, J

Boulet, J

Mark, L

Pearson, M

Gottshall, S

Walker, K

Schäfers, M

Marziniak, M

Sorkin, LS

Yaksh, TL

Sommer, C

Hsueh, SF

Lu, CY

Chao, CS

Tan, PH

Huang, YW

Hsieh, SW

Hsiao, HT

Chung, NC

Lin, SH

Huang, PL

Lyu, PC

Yang, LC

Zanchet, EM

Veiga, AP

Duarte, ID

Avila, MN

da Motta, PG

Yoshino, T

Kimoto, A

Kobayashi, S

Noguchi, M

Fukunaga, M

Hayashi, A

Miyata, K

Sasamata, M

Chichorro, JG

Zampronio, AR

Souza, GE

Rae, GA

Okumura, T

Sakakibara, A

Murata, Y

Kita, Y

Inglis, JJ

Notley, CA

Essex, D

Wilson, AW

Feldmann, M

Anand, P

Williams, R

Lee, IO

Seo, Y

Smith, CJ

Muhammad, J

Zweifel, BS

Shaffer, A

Masferrer, JL

Mazario, J

Gaitan, G

Herrero, JF

Clinical Trials (3)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
In Vivo Selectivity of Cyclooxygenase Inhibitors in the Oral Surgery Model[NCT00006299]	Phase 2	120 participants	Interventional	1999-12-31	Completed
Pain Modulation in RA - Influence of Adalimumab. A Randomized, Placebo-controlled Study Using Functional Magnetic Resonance Imaging (PARADE)[NCT01197144]		70 participants (Actual)	Interventional	2010-10-31	Completed
Cytokine Responses to Acute Inflammation in the Oral Surgery Model[NCT00006175]		160 participants	Observational	2000-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

In Vivo Selectivity of Cyclooxygenase Inhibitors in the Oral Surgery Model[NCT00006299]

Phase 2

120 participants

Interventional

1999-12-31

Completed

Pain Modulation in RA - Influence of Adalimumab. A Randomized, Placebo-controlled Study Using Functional Magnetic Resonance Imaging (PARADE)[NCT01197144]

70 participants (Actual)

Interventional

2010-10-31

Completed

Cytokine Responses to Acute Inflammation in the Oral Surgery Model[NCT00006175]

160 participants

Observational

2000-08-31

Completed

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

2 trials available for celecoxib and Allodynia

Article	Year
Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition. PloS one, 2016, Volume: 11, Issue:12 Topics: Adult; Aged; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female;	2016
Anti-hyperalgesic effects of nimesulide: studies in rats and humans. International journal of clinical practice. Supplement, 2002, Issue:128 Topics: Aged; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid;	2002

Article

Year

Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition.

PloS one, 2016, Volume: 11, Issue:12

Topics: Adult; Aged; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female;

2016

Anti-hyperalgesic effects of nimesulide: studies in rats and humans.

International journal of clinical practice. Supplement, 2002, Issue:128

Topics: Aged; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid;

2002

Other Studies

49 other studies available for celecoxib and Allodynia

Article	Year
Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). Journal of medicinal chemistry, 1997, Apr-25, Volume: 40, Issue:9 Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Carrageenan; Celecoxib; Cyclooxygenase 1; C	1997
2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors. Journal of medicinal chemistry, 1999, Apr-08, Volume: 42, Issue:7 Topics: Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Biological Availability; Carrageenan; Ce	1999
New celecoxib derivatives as anti-inflammatory agents. Journal of medicinal chemistry, 2008, Jan-10, Volume: 51, Issue:1 Topics: Acetic Acid; Animals; Carrageenan; Celecoxib; Chronic Disease; Crystallization; Cyclooxygenase 1; Cy	2008
Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. Bioorganic & medicinal chemistry, 2009, Jan-01, Volume: 17, Issue:1 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cell Line; Cyclooxygenase 2 Inhibitors; Disease Model	2009
Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties. Journal of medicinal chemistry, 2011, Nov-24, Volume: 54, Issue:22 Topics: Acetates; Animals; Cell Line; Constriction, Pathologic; Cyclooxygenase 2 Inhibitors; Edema; Esters;	2011
Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors. Bioorganic & medicinal chemistry, 2014, Jan-15, Volume: 22, Issue:2 Topics: Acetic Acid; Amides; Animals; Carrageenan; Cell Line; Constriction, Pathologic; Cyclooxygenase 2; Cy	2014
Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep). Journal of medicinal chemistry, 2015, May-14, Volume: 58, Issue:9 Topics: Analgesics; Animals; Benzimidazoles; Biological Availability; Carrageenan; Dogs; Freund's Adjuvant;	2015
Indole based peptidomimetics as anti-inflammatory and anti-hyperalgesic agents: Dual inhibition of 5-LOX and COX-2 enzymes. European journal of medicinal chemistry, 2015, Jun-05, Volume: 97 Topics: Animals; Anti-Inflammatory Agents; Catalytic Domain; Crystallography, X-Ray; Cyclooxygenase 2 Inhibi	2015
Regioselectively controlled synthesis of 3(5)-(trifluoromethyl)pyrazolylbenzenesulfonamides and their effects on a pathological pain model in mice. European journal of medicinal chemistry, 2015, Sep-18, Volume: 102 Topics: Animals; Celecoxib; Disease Models, Animal; Edema; Hydrocarbons, Fluorinated; Hyperalgesia; Male; Mi	2015
Tailoring the Substitution Pattern on 1,3,5-Triazine for Targeting Cyclooxygenase-2: Discovery and Structure-Activity Relationship of Triazine-4-Aminophenylmorpholin-3-one Hybrids that Reverse Algesia and Inflammation in Swiss Albino Mice. Journal of medicinal chemistry, 2018, 09-13, Volume: 61, Issue:17 Topics: Analgesics; Animals; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Drug D	2018
Modification of the lead molecule: Tryptophan and piperidine appended triazines reversing inflammation and hyeperalgesia in rats. Bioorganic & medicinal chemistry, 2020, 01-15, Volume: 28, Issue:2 Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 In	2020
1,4-Diaryl-1,2,3-triazole neolignan-celecoxib hybrids inhibit experimental arthritis induced by zymosan. Inflammopharmacology, 2023, Volume: 31, Issue:6 Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Edema;	2023
Nonsteroidal anti-inflammatory drugs and acetaminophen ameliorate muscular mechanical hyperalgesia developed after lengthening contractions via cyclooxygenase-2 independent mechanisms in rats. PloS one, 2019, Volume: 14, Issue:11 Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Hypera	2019
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. Neuropharmacology, 2020, Volume: 163 Topics: Amidohydrolases; Analgesics; Animals; Benzamides; Brain; Cannabidiol; Capsaicin; Carbamates; Celecox	2020
Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats. Behavioural pharmacology, 2021, 04-01, Volume: 32, Issue:2&3 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Models, Animal; Dos	2021
The Analgesic Effects of Celecoxib on the Formalin-induced Short- and Long-term Inflammatory Pain. Pain physician, 2017, Volume: 20, Issue:4 Topics: Analgesics; Animals; Celecoxib; Dose-Response Relationship, Drug; Formaldehyde; Hyperalgesia; Male;	2017
Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia. Neuropharmacology, 2017, Volume: 125 Topics: Acetaminophen; Analgesics; Animals; Arthritis; Celecoxib; Disease Models, Animal; Diterpenes; Female	2017
Salmon calcitonin exerts better preventive effects than celecoxib on lumbar facet joint degeneration and long-term tactile allodynia in rats. Bone, 2019, Volume: 127 Topics: Animals; Biomarkers; Calcitonin; Cartilage, Articular; Celecoxib; Hyperalgesia; Image Processing, Co	2019
Inhibition of COX-2 alleviates lumbar spinal stenosis-induced chronic mechanical allodynia in rats. International immunopharmacology, 2019, Volume: 75 Topics: Animals; Cauda Equina; Celecoxib; Chronic Pain; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytok	2019
Levetiracetam interacts synergistically with nonsteroidal analgesics and caffeine to produce antihyperalgesia in rats. The journal of pain, 2013, Volume: 14, Issue:11 Topics: Acetaminophen; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Celecoxib; Dr	2013
Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents. Anesthesiology, 2014, Volume: 120, Issue:3 Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Animals; Anti-Bacterial Agents; Ceftriaxone; Ce	2014
Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy. Pharmacological reports : PR, 2015, Volume: 67, Issue:2 Topics: Animals; Arachidonic Acids; Cannabinoids; Celecoxib; Cyclooxygenase Inhibitors; Diabetic Neuropathie	2015
Celecoxib reduces hyperalgesia and tactile allodynia in diabetic rats. Pharmacological reports : PR, 2015, Volume: 67, Issue:3 Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diabetes Mellitus, Experimental; Dose-Response Rela	2015
Circulating microRNA Signatures in Rodent Models of Pain. Molecular neurobiology, 2016, Volume: 53, Issue:5 Topics: Animals; Celecoxib; Circulating MicroRNA; Disease Models, Animal; Freund's Adjuvant; Gene Expression	2016
Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice. Brain, behavior, and immunity, 2017, Volume: 62 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemokine CCL5; Cyclooxygenase 2 Inhibi	2017
Synergistic anti-hyperalgesia of electroacupuncture and low dose of celecoxib in monoarthritic rats: involvement of the cyclooxygenase activity in the spinal cord. Brain research bulletin, 2008, Sep-30, Volume: 77, Issue:2-3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Behavior, Animal; Celecox	2008
The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation. The Journal of pharmacy and pharmacology, 2009, Volume: 61, Issue:5 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cel	2009
Cyclooxygenase inhibitors suppress the expression of P2X(3) receptors in the DRG and attenuate hyperalgesia following chronic constriction injury in rats. Neuroscience letters, 2010, Jul-05, Volume: 478, Issue:2 Topics: Animals; Celecoxib; Constriction, Pathologic; Cyclooxygenase Inhibitors; Ganglia, Spinal; Hot Temper	2010
Peripheral mu-, kappa- and delta-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia. Life sciences, 2010, Jun-19, Volume: 86, Issue:25-26 Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dose-Response	2010
Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity? Pharmacological research, 2010, Volume: 62, Issue:5 Topics: Acetazolamide; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationsh	2010
Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats. Neuropharmacology, 2010, Volume: 59, Issue:6 Topics: Analgesics; Analysis of Variance; Animals; Celecoxib; Dinoprostone; Hyperalgesia; Indomethacin; Infl	2010
A novel COX-2 inhibitor pyrazole derivative proven effective as an anti-inflammatory and analgesic drug. Basic & clinical pharmacology & toxicology, 2011, Volume: 108, Issue:4 Topics: Analgesics; Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Carrageenan; Celecoxib; Chronic	2011
Use of dynamic weight bearing as a novel end-point for the assessment of Freund's Complete Adjuvant induced hypersensitivity in mice. Neuroscience letters, 2012, Aug-30, Volume: 524, Issue:2 Topics: Adjuvants, Immunologic; Animals; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhibitors; Endpoint Dete	2012
Characterization of nerve growth factor-induced mechanical and thermal hypersensitivity in rats. European journal of pain (London, England), 2013, Volume: 17, Issue:4 Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; C	2013
Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. British journal of pharmacology, 2002, Volume: 137, Issue:6 Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhib	2002
Role of endogenous glucocorticoids in hyperalgesia and edema in old arthritic rats. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2003, Volume: 36, Issue:1 Topics: Adrenalectomy; Age Factors; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal;	2003
Hyperalgesia induced by Asp49 and Lys49 phospholipases A2 from Bothrops asper snake venom: pharmacological mediation and molecular determinants. Toxicon : official journal of the International Society on Toxinology, 2003, Volume: 41, Issue:6 Topics: Animals; Bothrops; Bradykinin; Carrageenan; Celecoxib; Crotalid Venoms; Heparin; Hindlimb; Histamine	2003
Pharmacological characterisation of a rat model of incisional pain. British journal of pharmacology, 2004, Volume: 141, Issue:1 Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Disease Model	2004
Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat. Experimental neurology, 2004, Volume: 185, Issue:1 Topics: Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase	2004
Nonsteroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation. Brain research. Molecular brain research, 2004, Jun-18, Volume: 125, Issue:1-2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhi	2004
Involvement of spinal neurokinins, excitatory amino acids, proinflammatory cytokines, nitric oxide and prostanoids in pain facilitation induced by Phoneutria nigriventer spider venom. Brain research, 2004, Sep-17, Volume: 1021, Issue:1 Topics: Animals; Antibodies; Calcitonin Gene-Related Peptide Receptor Antagonists; Celecoxib; Citrates; Cycl	2004
Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats. Life sciences, 2004, Oct-22, Volume: 75, Issue:23 Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Models, A	2004
Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor. Arzneimittel-Forschung, 2005, Volume: 55, Issue:7 Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy	2005
Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs. Pain, 2006, Volume: 123, Issue:1-2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atrasentan; Bosentan; Carrageenan; Celecoxib; Cold	2006
Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA. European journal of pharmacology, 2008, Jan-06, Volume: 578, Issue:1 Topics: Animals; Carrageenan; Celecoxib; Chlorobenzoates; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Din	2008
Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade. Arthritis and rheumatism, 2007, Volume: 56, Issue:12 Topics: Animals; Arthritis; Astrocytes; Behavior, Animal; Celecoxib; Collagen; Cyclooxygenase Inhibitors; Di	2007
The effects of intrathecal cyclooxygenase-1, cyclooxygenase-2, or nonselective inhibitors on pain behavior and spinal Fos-like immunoreactivity. Anesthesia and analgesia, 2008, Volume: 106, Issue:3 Topics: Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor	2008
Pharmacological analysis of cyclooxygenase-1 in inflammation. Proceedings of the National Academy of Sciences of the United States of America, 1998, Oct-27, Volume: 95, Issue:22 Topics: Animals; Arthritis, Experimental; Blood Platelets; Carrageenan; Celecoxib; Cyclooxygenase 1; Cycloox	1998
Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes. Neuropharmacology, 2001, Volume: 40, Issue:7 Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Celecoxib; Cy	2001

Article

Year

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).

Journal of medicinal chemistry, 1997, Apr-25, Volume: 40, Issue:9

Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Carrageenan; Celecoxib; Cyclooxygenase 1; C

1997

2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.

Journal of medicinal chemistry, 1999, Apr-08, Volume: 42, Issue:7

Topics: Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Biological Availability; Carrageenan; Ce

1999

New celecoxib derivatives as anti-inflammatory agents.

Journal of medicinal chemistry, 2008, Jan-10, Volume: 51, Issue:1

Topics: Acetic Acid; Animals; Carrageenan; Celecoxib; Chronic Disease; Crystallization; Cyclooxygenase 1; Cy

2008

Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes.

Bioorganic & medicinal chemistry, 2009, Jan-01, Volume: 17, Issue:1

Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cell Line; Cyclooxygenase 2 Inhibitors; Disease Model

2009

Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties.

Journal of medicinal chemistry, 2011, Nov-24, Volume: 54, Issue:22

Topics: Acetates; Animals; Cell Line; Constriction, Pathologic; Cyclooxygenase 2 Inhibitors; Edema; Esters;

2011

Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors.

Bioorganic & medicinal chemistry, 2014, Jan-15, Volume: 22, Issue:2

Topics: Acetic Acid; Amides; Animals; Carrageenan; Cell Line; Constriction, Pathologic; Cyclooxygenase 2; Cy

2014

Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep).

Journal of medicinal chemistry, 2015, May-14, Volume: 58, Issue:9

Topics: Analgesics; Animals; Benzimidazoles; Biological Availability; Carrageenan; Dogs; Freund's Adjuvant;

2015

Indole based peptidomimetics as anti-inflammatory and anti-hyperalgesic agents: Dual inhibition of 5-LOX and COX-2 enzymes.

European journal of medicinal chemistry, 2015, Jun-05, Volume: 97

Topics: Animals; Anti-Inflammatory Agents; Catalytic Domain; Crystallography, X-Ray; Cyclooxygenase 2 Inhibi

2015

Regioselectively controlled synthesis of 3(5)-(trifluoromethyl)pyrazolylbenzenesulfonamides and their effects on a pathological pain model in mice.

European journal of medicinal chemistry, 2015, Sep-18, Volume: 102

Topics: Animals; Celecoxib; Disease Models, Animal; Edema; Hydrocarbons, Fluorinated; Hyperalgesia; Male; Mi

2015

Tailoring the Substitution Pattern on 1,3,5-Triazine for Targeting Cyclooxygenase-2: Discovery and Structure-Activity Relationship of Triazine-4-Aminophenylmorpholin-3-one Hybrids that Reverse Algesia and Inflammation in Swiss Albino Mice.

Journal of medicinal chemistry, 2018, 09-13, Volume: 61, Issue:17

Topics: Analgesics; Animals; Carrageenan; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Drug D

2018

Modification of the lead molecule: Tryptophan and piperidine appended triazines reversing inflammation and hyeperalgesia in rats.

Bioorganic & medicinal chemistry, 2020, 01-15, Volume: 28, Issue:2

Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 In

2020

1,4-Diaryl-1,2,3-triazole neolignan-celecoxib hybrids inhibit experimental arthritis induced by zymosan.

Inflammopharmacology, 2023, Volume: 31, Issue:6

Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Celecoxib; Edema;

2023

Nonsteroidal anti-inflammatory drugs and acetaminophen ameliorate muscular mechanical hyperalgesia developed after lengthening contractions via cyclooxygenase-2 independent mechanisms in rats.

PloS one, 2019, Volume: 14, Issue:11

Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Hypera

2019

Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.

Neuropharmacology, 2020, Volume: 163

Topics: Amidohydrolases; Analgesics; Animals; Benzamides; Brain; Cannabidiol; Capsaicin; Carbamates; Celecox

2020

Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats.

Behavioural pharmacology, 2021, 04-01, Volume: 32, Issue:2&3

Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Models, Animal; Dos

2021

The Analgesic Effects of Celecoxib on the Formalin-induced Short- and Long-term Inflammatory Pain.

Pain physician, 2017, Volume: 20, Issue:4

Topics: Analgesics; Animals; Celecoxib; Dose-Response Relationship, Drug; Formaldehyde; Hyperalgesia; Male;

2017

Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia.

Neuropharmacology, 2017, Volume: 125

Topics: Acetaminophen; Analgesics; Animals; Arthritis; Celecoxib; Disease Models, Animal; Diterpenes; Female

2017

Salmon calcitonin exerts better preventive effects than celecoxib on lumbar facet joint degeneration and long-term tactile allodynia in rats.

Bone, 2019, Volume: 127

Topics: Animals; Biomarkers; Calcitonin; Cartilage, Articular; Celecoxib; Hyperalgesia; Image Processing, Co

2019

Inhibition of COX-2 alleviates lumbar spinal stenosis-induced chronic mechanical allodynia in rats.

International immunopharmacology, 2019, Volume: 75

Topics: Animals; Cauda Equina; Celecoxib; Chronic Pain; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytok

2019

Levetiracetam interacts synergistically with nonsteroidal analgesics and caffeine to produce antihyperalgesia in rats.

The journal of pain, 2013, Volume: 14, Issue:11

Topics: Acetaminophen; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Celecoxib; Dr

2013

Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents.

Anesthesiology, 2014, Volume: 120, Issue:3

Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Animals; Anti-Bacterial Agents; Ceftriaxone; Ce

2014

Influence of nitric oxide synthase or cyclooxygenase inhibitors on cannabinoids activity in streptozotocin-induced neuropathy.

Pharmacological reports : PR, 2015, Volume: 67, Issue:2

Topics: Animals; Arachidonic Acids; Cannabinoids; Celecoxib; Cyclooxygenase Inhibitors; Diabetic Neuropathie

2015

Celecoxib reduces hyperalgesia and tactile allodynia in diabetic rats.

Pharmacological reports : PR, 2015, Volume: 67, Issue:3

Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diabetes Mellitus, Experimental; Dose-Response Rela

2015

Circulating microRNA Signatures in Rodent Models of Pain.

Molecular neurobiology, 2016, Volume: 53, Issue:5

Topics: Animals; Celecoxib; Circulating MicroRNA; Disease Models, Animal; Freund's Adjuvant; Gene Expression

2016

Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice.

Brain, behavior, and immunity, 2017, Volume: 62

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemokine CCL5; Cyclooxygenase 2 Inhibi

2017

Synergistic anti-hyperalgesia of electroacupuncture and low dose of celecoxib in monoarthritic rats: involvement of the cyclooxygenase activity in the spinal cord.

Brain research bulletin, 2008, Sep-30, Volume: 77, Issue:2-3

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Behavior, Animal; Celecox

2008

The importance of brain PGE2 inhibition versus paw PGE2 inhibition as a mechanism for the separation of analgesic and antipyretic effects of lornoxicam in rats with paw inflammation.

The Journal of pharmacy and pharmacology, 2009, Volume: 61, Issue:5

Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cel

2009

Cyclooxygenase inhibitors suppress the expression of P2X(3) receptors in the DRG and attenuate hyperalgesia following chronic constriction injury in rats.

Neuroscience letters, 2010, Jul-05, Volume: 478, Issue:2

Topics: Animals; Celecoxib; Constriction, Pathologic; Cyclooxygenase Inhibitors; Ganglia, Spinal; Hot Temper

2010

Peripheral mu-, kappa- and delta-opioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia.

Life sciences, 2010, Jun-19, Volume: 86, Issue:25-26

Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dose-Response

2010

Is the sulphonamide radical in the celecoxib molecule essential for its analgesic activity?

Pharmacological research, 2010, Volume: 62, Issue:5

Topics: Acetazolamide; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationsh

2010

Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats.

Neuropharmacology, 2010, Volume: 59, Issue:6

Topics: Analgesics; Analysis of Variance; Animals; Celecoxib; Dinoprostone; Hyperalgesia; Indomethacin; Infl

2010

A novel COX-2 inhibitor pyrazole derivative proven effective as an anti-inflammatory and analgesic drug.

Basic & clinical pharmacology & toxicology, 2011, Volume: 108, Issue:4

Topics: Analgesics; Animals; Anti-Inflammatory Agents; Benzenesulfonamides; Carrageenan; Celecoxib; Chronic

2011

Use of dynamic weight bearing as a novel end-point for the assessment of Freund's Complete Adjuvant induced hypersensitivity in mice.

Neuroscience letters, 2012, Aug-30, Volume: 524, Issue:2

Topics: Adjuvants, Immunologic; Animals; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhibitors; Endpoint Dete

2012

Characterization of nerve growth factor-induced mechanical and thermal hypersensitivity in rats.

European journal of pain (London, England), 2013, Volume: 17, Issue:4

Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; C

2013

Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation.

British journal of pharmacology, 2002, Volume: 137, Issue:6

Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhib

2002

Role of endogenous glucocorticoids in hyperalgesia and edema in old arthritic rats.

Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2003, Volume: 36, Issue:1

Topics: Adrenalectomy; Age Factors; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal;

2003

Hyperalgesia induced by Asp49 and Lys49 phospholipases A2 from Bothrops asper snake venom: pharmacological mediation and molecular determinants.

Toxicon : official journal of the International Society on Toxinology, 2003, Volume: 41, Issue:6

Topics: Animals; Bothrops; Bradykinin; Carrageenan; Celecoxib; Crotalid Venoms; Heparin; Hindlimb; Histamine

2003

Pharmacological characterisation of a rat model of incisional pain.

British journal of pharmacology, 2004, Volume: 141, Issue:1

Topics: Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Disease Model

2004

Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat.

Experimental neurology, 2004, Volume: 185, Issue:1

Topics: Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase

2004

Nonsteroidal anti-inflammatory drugs increase expression of inducible COX-2 isoform of cyclooxygenase in spinal cord of rats with adjuvant induced inflammation.

Brain research. Molecular brain research, 2004, Jun-18, Volume: 125, Issue:1-2

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhi

2004

Involvement of spinal neurokinins, excitatory amino acids, proinflammatory cytokines, nitric oxide and prostanoids in pain facilitation induced by Phoneutria nigriventer spider venom.

Brain research, 2004, Sep-17, Volume: 1021, Issue:1

Topics: Animals; Antibodies; Calcitonin Gene-Related Peptide Receptor Antagonists; Celecoxib; Citrates; Cycl

2004

Prevention by celecoxib of secondary hyperalgesia induced by formalin in rats.

Life sciences, 2004, Oct-22, Volume: 75, Issue:23

Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Models, A

2004

Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.

Arzneimittel-Forschung, 2005, Volume: 55, Issue:7

Topics: Animals; Carrageenan; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cy

2005

Orofacial cold hyperalgesia due to infraorbital nerve constriction injury in rats: reversal by endothelin receptor antagonists but not non-steroidal anti-inflammatory drugs.

Pain, 2006, Volume: 123, Issue:1-2

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atrasentan; Bosentan; Carrageenan; Celecoxib; Cold

2006

Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA.

European journal of pharmacology, 2008, Jan-06, Volume: 578, Issue:1

Topics: Animals; Carrageenan; Celecoxib; Chlorobenzoates; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Din

2008

Collagen-induced arthritis as a model of hyperalgesia: functional and cellular analysis of the analgesic actions of tumor necrosis factor blockade.

Arthritis and rheumatism, 2007, Volume: 56, Issue:12

Topics: Animals; Arthritis; Astrocytes; Behavior, Animal; Celecoxib; Collagen; Cyclooxygenase Inhibitors; Di

2007

The effects of intrathecal cyclooxygenase-1, cyclooxygenase-2, or nonselective inhibitors on pain behavior and spinal Fos-like immunoreactivity.

Anesthesia and analgesia, 2008, Volume: 106, Issue:3

Topics: Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor

2008

Pharmacological analysis of cyclooxygenase-1 in inflammation.

Proceedings of the National Academy of Sciences of the United States of America, 1998, Oct-27, Volume: 95, Issue:22

Topics: Animals; Arthritis, Experimental; Blood Platelets; Carrageenan; Celecoxib; Cyclooxygenase 1; Cycloox

1998

Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes.

Neuropharmacology, 2001, Volume: 40, Issue:7

Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Celecoxib; Cy

2001